Aliases:This biomarker is also known as:
- keratin, type I cytoskeletal 19,
- Cytokeratin 19,
- keratin, type I, 40-kd,
- keratin 19,
- 40-kDa keratin intermediate filament,
- cytokeratin 19,
KRT19, a member of the keratin family which exists as a heterotetramer of two type I and two type II keratins, is involved in the organization of myofibers. Together with KRT8, KRT19 helps to link the contractile apparatus to dystrophin at the costameres of striated muscle. KRT18 is expressed in a defined zone of basal keratinocytes in the deep outer root sheath of hair follicles. It is also observed in sweat gland and mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, ectocervical epithelium (at protein level). It is expressed in epidermal basal cells and in nipple epidermis. It is also evident in a subset of vascular wall cells in both the veins and artery of human umbilical cord, and in umbilical cord vascular smooth muscle, as well as in muscle fibers accumulating in the costameres of myoplasm at the sarcolemma in structures that contain dystrophin and spectrin.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
KRT19 (keratin 19) has been shown to be a helpful biomarker in differentiating procarcinoma from squamous cell carcinoma when screened as part of a panel including keratin 7 (KRT7), keratin 19 and nestin (NES). An assay composed of KRT19, KRT8, and KRT18 has been used to detect, measure, and evaluate circulating tumor cells (CTCs) in the blood of healthy and metastatic patients.
Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.
|QA State:||Under Review|
- An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma.
- Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.